N@N

ImmunoGen, Inc. Announces Webcast of Presentation at the Bank of America Merrill Lynch Health Care Conference

^{Published on 2010-05-08 09:00:34 - Market Wire}
 

WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (Nasdaq: IMGN) is scheduled to present at the Bank of America Merrill Lynch Health Care Conference at 1:40pmET on May13, 2010. The Conference is being held at the Grand Hyatt New York. ImmunoGena™s presentation will be webcast live and can be accessed through the aInvestor Informationa section of our website, [ www.immunogen.com ]. An archive of the webcast will be available at the same location until May 20, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Companya™s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGena™s potent cell-killing agents specifically to tumor targets. In addition to the Companya™s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGena™s collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in PhaseIII testing being conducted by Genentech/Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at [ www.immunogen.com ].